Tablets & Capsules

TC0717

Issue link: https://www.e-digitaleditions.com/i/845331

Contents of this Issue

Navigation

Page 22 of 57

Tablets & Capsules July 2017 21 Figure 1 Typical control strategy considerations Patient consideration •Oral administration: Tablet, capsule Documentation •Batch records •Development reports Prior knowledge Personnel qualifications and training Drug substance •Physicochemical characteristics •Specifications and test methods Product design •Excipient characteristics •Excipient use levels •IR, MR tablet or capsule Facilities •Containment requirements •Temperature •Humidity Equipment design and operating principles Regulation and guidance documents •ICH, Q8, Q9, Q10, and Q11 •FDA, EMA Excipients •Physicochemical properties •Specifications and test methods Product manufacture •In-process controls º Frequency of monitoring •Controls for intermediate materials Drug product specifications and test methods Labeling •Usage directions •Special storage, handling, etc. Container/closure •Bottle/cap composition, size •Blister composition Quality verification Stability of product •Expiration date •In-use •Hold times C O N T R O L S T R A T E G Y

Articles in this issue

Archives of this issue

view archives of Tablets & Capsules - TC0717